Addex Therapeutics announced that Janssen Pharmaceuticals (J&J Innovative Medicine) has discontinued the development of ADX71149 in epilepsy following unsuccessful Phase 2 trial results. The April 2024 top-line data showed that ADX71149 as an adjunctive treatment failed to achieve statistical significance in patients with focal onset seizures who had suboptimal response to standard therapies.The partnership between Addex and Janssen remains active while they analyze the complete Phase 2 dataset. Under their collaboration agreement, Addex is eligible for up to €109 million in development and regulatory milestone payments, plus low double-digit royalties on net sales. ADX71149, a selective metabotropic glutamate subtype 2 receptor positive allosteric modulator, was evaluated in a multi-center study focusing on its efficacy when combined with levetiracetam or brivaracetam.The study was conducted in two parts: a 4-week acute efficacy phase followed by an 8-week maintenance phase for qualifying patients. The primary endpoint measured the time for patients to reach baseline seizure count when ADX71149 was added to standard care.

Addex Therapeutics announced that Janssen Pharmaceuticals (J&J Innovative Medicine) has discontinued the development of ADX71149 in epilepsy following unsuccessful Phase 2 trial results. The April 2024 top-line data showed that ADX71149 as an adjunctive treatment failed to achieve statistical significance in patients with focal onset seizures who had suboptimal response to standard therapies.The partnership between Addex and Janssen remains active while they analyze the complete Phase 2 dataset. Under their collaboration agreement, Addex is eligible for up to €109 million in development and regulatory milestone payments, plus low double-digit royalties on net sales. ADX71149, a selective metabotropic glutamate subtype 2 receptor positive allosteric modulator, was evaluated in a multi-center study focusing on its efficacy when combined with levetiracetam or brivaracetam.The study was conducted in two parts: a 4-week acute efficacy phase followed by an 8-week maintenance phase for qualifying patients. The primary endpoint measured the time for patients to reach baseline seizure count when ADX71149 was added to standard care.